我院抗肿瘤辅助用药分析及干预措施

发布时间：2018-04-23 08:07

本文选题：抗肿瘤辅助用药 + 分析　；参考：《中国药房》2015年11期

【摘要】：目的:促进抗肿瘤辅助用药的安全、合理和经济使用。方法:回顾性分析我院2013年1-6月(干预前)和7-12月(干预后)抗肿瘤辅助用药应用情况及评价干预效果。结果:通过技术干预、行政干预、信息干预等措施,不合理使用抗肿瘤辅助用药得到有效改善,抗肿瘤辅助用药占药品总收入的比例,干预前为59.07%,干预后为47.17%,下降11.90%。结论:肿瘤治疗中辅助用药目前尚缺少客观和系统的评价依据,通过临床查找循证证据,客观评价用药合理性,逐步规范辅助用药行为,可以规避用药风险。
[Abstract]:Objective: to promote the safety, rational and economical use of antitumor adjuvant drugs. Methods: the application of antitumor adjuvant drugs in our hospital from January to June 2013 (before intervention) and from July to December (after intervention) were analyzed retrospectively and the effect of intervention was evaluated. Results: through technical intervention, administrative intervention, information intervention and other measures, the irrational use of anti-tumor adjuvant drugs was effectively improved. The proportion of anti-tumor adjuvant drugs in the total income of drugs was 59.07 before intervention, 47.17 after intervention, and decreased by 11.90. Conclusion: there is no objective and systematic evaluation basis for adjuvant drug use in tumor therapy at present. The risk of drug use can be avoided by looking up evidence based on evidence objectively evaluating the rationality of drug use and standardizing the behavior of adjuvant drug use step by step.
【作者单位】：南通市肿瘤医院药剂科;
【分类号】：R95

【参考文献】